合并社区获得性肺炎的心力衰竭患者抗生素使用分析
Analysis of Antibiotic Use in Patients with Community-Acquired Pneumonia and Heart Failure
DOI: 10.12677/acm.2025.152564, PDF,   
作者: 武思岐*, 韩逸初*, 任景怡#:中日友好医院/北京协和医学院/中国医学科学院,北京
关键词: 心力衰竭社区获得性肺炎抗生素β内酰胺类喹诺酮类Heart Failure Community-Acquired Pneumonia Antibiotics Beta-Lactams Quinolones
摘要: 背景:肺炎是诱发急性心力衰竭最常见的诱因之一,临床最常用的β酰胺类与喹诺酮类抗生素对于合并社区获得性肺炎的心力衰竭患者预后尚不清楚。本研究旨在比较两类抗生素对合并社区获得性肺炎的心力衰竭患者预后影响,并分析此类人群再住院相关的预测因子。方法与结果:本研究共纳入548例心力衰竭合并社区获得性肺炎患者。共有429例患者使用抗生素。此类人群最常用的抗生素分别为β内酰胺类(77.2%)、喹诺酮类(44.1%)、大环内酯类(11.7%)。根据单独使用β内酰胺类及喹诺酮类抗生素分组,106例单独使用β酰胺类(62.0%),65例单独使用喹诺酮类(38.0%)。两组患者基线特征平衡。logistic回归分析表明两种抗生素对合并社区获得性肺炎的心力衰竭患者30天内再入院或院内死亡的复合终点发生风险无差异(21.7% vs 13.8%, P = 0.205)。进一步多因素回归分析发现合并冠心病、肾功能不全、脑梗死的患者发生30天内再入院或院内死亡的风险分别是不合并上述并发症患者的7.48倍(OR: 7.48; 95%CI: 2.03~27.59; P < 0.01)、4.02倍(OR: 4.02; 95%CI: 1.38~11.76; P = 0.01)及4.32倍(OR: 4.32; 95%CI: 1.46~12.77; P < 0.01)。结论:使用β内酰胺类及喹诺酮类抗生素对于合并社区获得性肺炎的心力衰竭患者预后无显著差异。合并冠心病、肾功能不全、脑梗死的患者预后更差,需要及早识别并积极治疗。
Abstract: Background: Pneumonia is one of the most common causes of acute heart failure. The prognosis for patients with heart failure who are also suffering from community-acquired pneumonia and are treated with the commonly used β-lactam and quinolone antibiotics is not well understood. This study aims to compare the impact of these two types of antibiotics on the prognosis of heart failure patients with community-acquired pneumonia and to analyze the predictive factors for readmission in this population. Methods and Results: A total of 548 patients with heart failure and community-acquired pneumonia were included in this study. Of these, 429 patients received antibiotics. The most commonly used antibiotics were β-lactams (77.2%), quinolones (44.1%), and macrolides (11.7%). Based on the use of β-lactams or quinolones alone, 106 patients received β-lactams alone (62.0%), and 65 patients received quinolones alone (38.0%). The baseline characteristics of the two groups were balanced. Logistic regression analysis indicated that there was no difference in the risk of the composite endpoint of readmission within 30 days or in-hospital death between the two types of antibiotics (21.7% vs 13.8%, P = 0.205). Further multivariate regression analysis found that patients with comorbidities such as coronary heart disease, renal insufficiency, and cerebral infarction had a risk of readmission within 30 days or in-hospital death that was 7.48 times (OR: 7.48; 95%CI: 2.03 ~ 27.59; P < 0.01), 4.02 times (OR: 4.02; 95%CI: 1.38~11.76; P = 0.01), and 4.32 times (OR: 4.32; 95%CI: 1.46~12.77; P < 0.01) higher, respectively, than those without these complications. Conclusion: There is no significant difference in the prognosis of heart failure patients with community-acquired pneumonia treated with β-lactam or quinolone antibiotics. Patients with comorbidities such as coronary heart disease, renal insufficiency, and cerebral infarction have a worse prognosis and require early identification and active treatment.
文章引用:武思岐, 韩逸初, 任景怡. 合并社区获得性肺炎的心力衰竭患者抗生素使用分析[J]. 临床医学进展, 2025, 15(2): 2018-2027. https://doi.org/10.12677/acm.2025.152564

参考文献

[1] Tralhão, A. and Póvoa, P. (2020) Cardiovascular Events after Community-Acquired Pneumonia: A Global Perspective with Systematic Review and Meta-Analysis of Observational Studies. Journal of Clinical Medicine, 9, Article 414. [Google Scholar] [CrossRef] [PubMed]
[2] Vaughn, V.M., Dickson, R.P., Horowitz, J.K. and Flanders, S.A. (2024) Community-Acquired Pneumonia. Journal of the American Medical Association, 332, 1282-1295. [Google Scholar] [CrossRef] [PubMed]
[3] Savarese, G., Becher, P.M., Lund, L.H., Seferovic, P., Rosano, G.M.C. and Coats, A.J.S. (2022) Global Burden of Heart Failure: A Comprehensive and Updated Review of Epidemiology. Cardiovascular Research, 118, 3272-3287. [Google Scholar] [CrossRef] [PubMed]
[4] Fonarow, G.C. (2008) Factors Identified as Precipitating Hospital Admissions for Heart Failure and Clinical Outcomesfindings from Optimize-HF. Archives of Internal Medicine, 168, 847-854. [Google Scholar] [CrossRef] [PubMed]
[5] Dai, S., Walsh, P., Wielgosz, A., Gurevich, Y., Bancej, C. and Morrison, H. (2012) Comorbidities and Mortality Associated with Hospitalized Heart Failure in Canada. Canadian Journal of Cardiology, 28, 74-79. [Google Scholar] [CrossRef] [PubMed]
[6] Shafazand, M., Patel, H., Ekman, I., Swedberg, K. and Schaufelberger, M. (2012) Patients with Worsening Chronic Heart Failure Who Present to a Hospital Emergency Department Require Hospital Care. BMC Research Notes, 5, Article No. 132. [Google Scholar] [CrossRef] [PubMed]
[7] Shen, L., Jhund, P.S., Anand, I.S., Bhatt, A.S., Desai, A.S., Maggioni, A.P., et al. (2021) Incidence and Outcomes of Pneumonia in Patients with Heart Failure. Journal of the American College of Cardiology, 77, 1961-1973. [Google Scholar] [CrossRef] [PubMed]
[8] Alon, D., Stein, G.Y., Korenfeld, R. and Fuchs, S. (2013) Predictors and Outcomes of Infection-Related Hospital Admissions of Heart Failure Patients. PLOS ONE, 8, e72476. [Google Scholar] [CrossRef] [PubMed]
[9] Musher, D.M., Rueda, A.M., Kaka, A.S. and Mapara, S.M. (2007) The Association between Pneumococcal Pneumonia and Acute Cardiac Events. Clinical Infectious Diseases, 45, 158-165. [Google Scholar] [CrossRef] [PubMed]
[10] Corrales-Medina, V.F., Madjid, M. and Musher, D.M. (2010) Role of Acute Infection in Triggering Acute Coronary Syndromes. The Lancet Infectious Diseases, 10, 83-92. [Google Scholar] [CrossRef] [PubMed]
[11] Chirinos, J.A. and Segers, P. (2010) Noninvasive Evaluation of Left Ventricular Afterload. Hypertension, 56, 563-570. [Google Scholar] [CrossRef] [PubMed]
[12] Harford, C.G. and Hara, M.N. (1947) Effect of Pulmonary Edema on Susceptibility of Mice to Pneumococcal Pneumonia. Proceedings of the Annual Meeting Center Society Clinical Research US, 20, Article No. 15.
[13] LaForce, F.M., Mullane, J.F., Boehme, R.F., Kelly, W.J. and Huber, G.L. (1973) The Effect of Pulmonary Edema on Antibacterial Defenses of the Lung. Journal of Laboratory and Clinical Medicine, 82, 634-648.
[14] 中华医学会呼吸病学分会. 中国成人社区获得性肺炎诊断和治疗指南(2016年版) [J]. 中国结核和呼吸杂志, 2016, 39(4): 1-27.
[15] Metlay, J.P., Waterer, G.W., Long, A.C., Anzueto, A., Brozek, J., Crothers, K., et al. (2019) Diagnosis and Treatment of Adults with Community-Acquired Pneumonia. an Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine, 200, e45-e67. [Google Scholar] [CrossRef] [PubMed]
[16] Timler, M., Timler, W., Bednarz, A., Zakonnik, Ł., Kozłowski, R., Timler, D., et al. (2023) Identification and Preliminary Hierarchisation of Selected Risk Factors for Carbapenemase-Producing Enterobacteriaceae (CPE) Colonisation: A Prospective Study. International Journal of Environmental Research and Public Health, 20, Article 1960. [Google Scholar] [CrossRef] [PubMed]
[17] Qian, Y., Bi, Y., Liu, S., Li, X., Dong, S. and Ju, M. (2021) Predictors of Mortality in Patients with Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Meta-Analysis and a Systematic Review. Annals of Palliative Medicine, 10, 7340-7350. [Google Scholar] [CrossRef] [PubMed]
[18] 段咏梅, 刘成, 安园园 , 等. 老年心力衰竭合并肺炎患者病原菌分布、炎性因子变化及预后分析[J]. 中国分子心脏病学杂志, 2023, 23(1): 5172-5176.
[19] Jiang, Y., Dou, H., Xu, B., Xu, B., Zhou, W., Wang, H., et al. (2024) Macrolide Resistance Ofmycoplasma Pneumoniaein Several Regions of China from 2013 to 2019. Epidemiology and Infection, 152, e75. [Google Scholar] [CrossRef] [PubMed]
[20] Corrales-Medina, V.F. and van Walraven, C. (2023) Guideline-Concordant Antibiotic Therapy for the Hospital Treatment of Community-Acquired Pneumonia and 1-Year All-Cause and Cardiovascular Mortality in Older Adult Patients Surviving to Discharge. Chest, 163, 1380-1389. [Google Scholar] [CrossRef] [PubMed]
[21] 孙铁英. 从指南看呼吸喹诺酮类药物在下呼吸道感染中的治疗地位[J]. 临床药物治疗, 2019, 17(12): 29-32.
[22] Gorelik, E., Masarwa, R., Perlman, A., Rotshild, V., Abbasi, M., Muszkat, M., et al. (2018) Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-Analysis and Network Meta-Analysis. Drug Safety, 42, 529-538. [Google Scholar] [CrossRef] [PubMed]
[23] 李陆, 房德敏, 陈青, 等. 喹诺酮类药物致QT间期延长的系统性回顾分析[J]. 天津药学, 2019, 31(2): 15-21.
[24] Sethi, N.J., Safi, S., Korang, S.K., Hróbjartsson, A., Skoog, M., Gluud, C., et al. (2021) Antibiotics for Secondary Prevention of Coronary Heart Disease. Wiley. [Google Scholar] [CrossRef] [PubMed]
[25] Chahine, B. (2021) Antibiotic Dosing Adjustments in Hospitalized Patients with Chronic Kidney Disease: A Retrospective Chart Review. International Urology and Nephrology, 54, 157-163. [Google Scholar] [CrossRef] [PubMed]